Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by research analysts at Mizuho in a research report issued to clients and investors on Monday. They presently have a $95.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $83.00. Mizuho’s price objective indicates a potential upside of 18.54% from the company’s current price.
GILD has been the subject of a number of other research reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Credit Suisse Group restated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Finally, ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus price target of $87.04.
Shares of Gilead Sciences (NASDAQ:GILD) traded up $0.82 during trading hours on Monday, reaching $80.14. 9,972,034 shares of the company were exchanged, compared to its average volume of 9,910,000. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. The firm has a market capitalization of $104,660.00, a P/E ratio of 23.03, a P/E/G ratio of -1.77 and a beta of 1.22. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54.
In other Gilead Sciences news, EVP James R. Meyers sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the sale, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the sale, the chairman now directly owns 3,046,766 shares of the company’s stock, valued at $254,587,766.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 358,333 shares of company stock valued at $28,066,908. Corporate insiders own 1.30% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in shares of Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after buying an additional 1,937,031 shares during the period. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after buying an additional 310,607 shares during the period. FMR LLC grew its stake in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after buying an additional 258,005 shares during the period. Finally, Parnassus Investments CA grew its stake in shares of Gilead Sciences by 2.5% during the 4th quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after buying an additional 464,609 shares during the period. 76.47% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Gilead Sciences (GILD) Receives Buy Rating from Mizuho” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/12/gilead-sciences-gild-receives-buy-rating-from-mizuho.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.